Latest News and Press Releases

Long-term survivors in both oral PV-10 arms showed an absence of gross bladder tumor at necropsy, a finding not observed in any untreated, vehicle-control, or anti-PD-1 monotherapy animal. KNOXVILLE,...

WASHINGTON, DC, May 15, 2026 (GLOBE NEWSWIRE) -- From new immunotherapy approaches to insights into environmental risk, research presented at the American Urological Association (AUA) Annual Meeting...

UroGen Announces New Data from the pivotal ENVISION trial that Shows ZUSUDRI DOR of Three Years

UroGen announces that the pivotal ENVISION 24 mo. Duration of Response date has been published online in The Journal of Urology.

Dublin, March 30, 2026 (GLOBE NEWSWIRE) -- The "Non-Muscle Invasive Bladder Cancer Market Report 2026" has been added to ResearchAndMarkets.com's offering. The non-muscle invasive bladder...

BCAN Launches News Faces of Bladder Cancer Report based on a survey of 1,100 patients.

Opportunistic refinancing meaningfully reduces cost of capital with 8.25% fixed interest rate and extends amortization period to Q1 2030 $200 million funded at closing to refinance the existing $125...

New data from the pivotal ENVISION trial with ZUSDURI shows durable complete responses across EORTC risk groups. Data presented at ASCO GU 2026.

PRINCETON, N.J., Feb. 24, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and...

PRINCETON, N.J., Feb. 23, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and...